Arginine Therapy for Pain in Children with Sickle Cell Disease
Phase 1/2
21
about 11 years
7–21
2 sites in GA
About this study
This trial is testing whether giving extra arginine to children with sickle cell disease will reduce pain, decrease the need for pain medication, or shorten hospital stays. It involves different ways of administering arginine.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Arginine
- 2.Take Arginine (Continuous)
- 3.Take Arginine (Loading)
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Therapeutic Nutrients/Minerals/Electrolytes (Biological Macromolecular Activity)
oral (Oral Capsule)
Primary: Pharmacokinetics of IV arginine, measured by plasma arginine concentration over time
Secondary: Apparent clearance of arginine, Area Under the Plasma Concentration -Time Curve (AUC) From Time 0 to the Time of the Last Quantifiable Concentration for Arginine, Terminal elimination half-life (t1/2) for arginine